12:23 PM
Dec 10, 2018
 |  BC Extra  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Editor's Note: This article was updated on Dec 10, 2018 at 5:10 PM PST

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he becomes chairman and CEO of Gilead Sciences Inc. (NASDAQ:GILD) next spring.

Genentech Inc. CEO Bill Anderson will succeed O’Day as CEO of the Roche (SIX:ROG; OTCQX:RHHBY) pharmaceuticals division on Jan. 1. O’Day, who will step down Dec. 31, will provide support for the transition until he joins Gilead March 1 (see "Genentech's Anderson to Succeed O'Day at Roche").

O'Day succeeds John Milligan as CEO. Together with Chairman John Martin, Milligan grew Gilead into a multibillion dollar biotech bellwether driven by the company's HIV and HCV franchises. Milligan became CEO in March 2016, succeeding Martin who served as...

Read the full 648 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >